Literature DB >> 11716659

Fecal occult blood test use by Kansas medicare beneficiaries.

K K Engelman1, E F Ellerbeck, J S Ahluwalia, N Nazir, A Velasco.   

Abstract

PURPOSE: The aim of this study was to examine utilization of and trends in fecal occult blood testing (FOBT) among beneficiaries since Medicare began FOBT coverage on January 1, 1998.
METHODS: We identified Kansas Medicare beneficiaries ages 65-79. Using Medicare claims, we determined which beneficiaries received FOBT during 1998-1999. We examined demographic variables associated with FOBT and rate changes over time. We linked beneficiaries to primary care practices (PCPs) and examined FOBT variations among 483 PCPs.
RESULTS: FOBT use remained unchanged during the study period. Of the 215,322 beneficiaries, 11% received at least one FOBT in 1998 and 11% in 1999; 18% had at least one test during the 2-year period, but only 4% had a test during both years. Caucasians and females had the highest FOBT rates. Although FOBT rates among PCPs ranged from 0 to 71%, only 19% of the practice rates exceeded 10%.
CONCLUSIONS: Few beneficiaries obtain annual FOBT and little change in rates has occurred since Medicare reimbursement began. Although FOBT rates vary widely between PCPs, most either do not provide FOBT or do not bill Medicare for FOBT. The FOBT claims rate is much lower than reported in patient surveys and may indicate that Medicare should reexamine its reimbursement policy. Copyright 2001 American Health Foundation and Elsevier Science.

Entities:  

Mesh:

Year:  2001        PMID: 11716659     DOI: 10.1006/pmed.2001.0936

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  6 in total

1.  Use of preventive services by men enrolled in Medicare+Choice plans.

Authors:  Leo S Morales; Jeannette Rogowski; Vicki A Freedman; Steven L Wickstrom; John L Adams; José J Escarce
Journal:  Am J Public Health       Date:  2004-05       Impact factor: 9.308

2.  Third Annual Fecal Occult Blood Testing in Community Health Clinics.

Authors:  Connie L Arnold; Alfred Rademaker; Michael S Wolf; Dachao Liu; Jill Hancock; Terry C Davis
Journal:  Am J Health Behav       Date:  2016-05

3.  Comparing the effectiveness of competing tests for reducing colorectal cancer mortality: a network meta-analysis.

Authors:  B Joseph Elmunzer; Amit G Singal; Jeremy B Sussman; Amar R Deshpande; Daniel A Sussman; Marisa L Conte; Ben A Dwamena; Mary A M Rogers; Philip S Schoenfeld; John M Inadomi; Sameer D Saini; Akbar K Waljee
Journal:  Gastrointest Endosc       Date:  2015-03       Impact factor: 9.427

4.  Strategies to improve repeat fecal occult blood testing cancer screening.

Authors:  Terry C Davis; Connie L Arnold; Charles L Bennett; Michael S Wolf; Cristalyn Reynolds; Dachao Liu; Alfred Rademaker
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-11-05       Impact factor: 4.254

5.  Increasing colorectal cancer testing: translating physician interventions into population-based practice.

Authors:  Anna P Schenck; Sharon Peacock; Michael Pignone; Eric Jackson; Nelson Gunter; Carrie N Klabunde
Journal:  Health Care Financ Rev       Date:  2006

6.  Persistent demographic differences in colorectal cancer screening utilization despite Medicare reimbursement.

Authors:  Cynthia W Ko; William Kreuter; Laura-Mae Baldwin
Journal:  BMC Gastroenterol       Date:  2005-03-08       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.